Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-07-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.102.2.149PMID 10889124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.

  2000cited by this paper
• Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.

  2000cited by this paper
• Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.

  2000cited by this paper
• Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.

  2000cited by this paper
• Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.

  2000cited by this paper
• Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.

  1999cited by this paper
• Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

  1999cited by this paper
• Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

  1998cited by this paper
• Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.

  1998cited by this paper
• International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

  1998cited by this paper
• Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

  1998cited by this paper
• Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.

  1998cited by this paper
• Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood.

  1998cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors

  1998cited by this paper
• Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

  1997cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.

  1995cited by this paper
• Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

  1995cited by this paper
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

  1994cited by this paper
• Ligands “activate” integrin αIIbβ3 (platelet GPIIb-IIIa)

  1991cited by this paper
• Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

  1991cited by this paper
• Designs for group sequential tests.

  1984cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Clinical Outcomes With Postprocedural Anticoagulation Versus No Anticoagulation in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: A Meta-Analysis.

  2025cites this paper
• Efficacy of high sensitivity C-reactive protein, lipoprotein A and troponin I levels in predicting cardiovascular disease severity on coronary angiogram - A prospective study

  2025cites this paper
• An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives

  2023cites this paper
• Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice

  2023cites this paper
• The Prognostic Value of Biomarkers in Non-ST-Elevation Acute Coronary Syndrome Patients that are Treated by an Early Invasive Strategy: Insights from the OPTIMA-2 Trial

  2023cites this paper
• Emerging therapeutic opportunities for integrin inhibitors

  2021cites this paper
• Exogenous Integrin αIIbβ3 Inhibitors Revisited: Past, Present and Future Applications

  2021cites this paper
• How not to discover a drug - integrins

  2020cites this paper
• Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting

  2019cites this paper
• Association of Catalytic (Labile) Iron with Cardiovascular Morbidity and Mortality

  2017cites this paper
• Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence

  2017cites this paper
• Glycosylated hemoglobin and leukoglycemic index as prognostic determinations in acute coronary syndrome

  2017cites this paper
• Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials

  2016cites this paper
• Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease

  2016cites this paper
• Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After PCI

  2016cites this paper
• Anti-platelet therapy in small animal medicine.

  2016cites this paper
• Pharmacogenomics of platelet inhibitors

  2016cites this paper
• Oral Antiplatelet Agents in PCI

  2016cites this paper
• Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years

  2015cites this paper
• Aortic and Mitral Calcification Is Marker of Significant Carotid and Limb Atherosclerosis in Patients with First Acute Coronary Syndrome

  2015cites this paper
• Aggravation of coronary heart disease: the balance of risk and the risk of disease treatment

  2015cites this paper
• Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.

  2015cites this paper
• Targeting Integrin and Integrin Signaling in Treating Thrombosis

  2015cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery

  2014cites this paper
• Cardiac evaluation and management before vascular surgery

  2014cites this paper
• Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.

  2014cites this paper
• Investigation of the role of platelet turnover on platelet inhibition and thrombus formation with regard to antiplatelet therapy

  2014cites this paper
• Triple Antiplatelet Therapy in Acute Coronary Syndrome in 2014

  2014cites this paper
• 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cites this paper
• antagonist Roxifiban: implications for the etiology of thrombocytopenia of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa Prospective testing for drug-dependent antibodies reduces the incidence

  2013cites this paper
• Perioperative evaluation of cardiac surgical risk: particularities in the emergency surgery – from the guidelines to the clinical practice

  2013cites this paper
• Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes)

  2013cites this paper
• Impact of peripheral vascular disease on short- and long-term outcomes in patients undergoing non-emergent percutaneous coronary intervention in the drug-eluting stent era.

  2013cites this paper
• Polymorphisms With Coronary Artery Disease Cardiovascular Risk: Association Of Type III Collagen COL3A1 Genetic Variability In The Extracellular Matrix As A Determinant Of

  2013cites this paper
• Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes

  2013cites this paper
• A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction.

  2012cites this paper
• Association between endothelin type A receptor haplotypes and mortality in coronary heart disease.

  2012cites this paper
• Wskaźnik filtracji kłębuszkowej jako marker rokowniczy w ostrych zespołach wieńcowych bez uniesienia odcinka ST

  2012cites this paper
• Abciximab

  2012cites this paper
• 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

  2011cites this paper
• Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.

  2011cites this paper
• Risk Stratification in Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction

  2011cites this paper
• Cancer Chemoprevention—the Cardiovascular Model

  2011cites this paper
• Simultaneous Release of a Hydroxy-Methylglutaryl Coenzyme A Reductase Inhibitor and a Glycoprotein IIb/IIIa Antagonist from a Thermoresponsive NiPAAm/NtBAAm Copolymer System

  2011cites this paper
• 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c

  2011cites this paper
• Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.

  2011cites this paper
• Cardiology—In‐Depth Look: Advances in Antiplatelet Therapy

  2011cites this paper
• Diabetes, ventricular dysfunction and acute coronary syndrome: an explosive triad.

  2011cites this paper
• 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• Current issues with glycoprotein IIb-IIIa antagonists.

  2011cites this paper
• CURRENT STATUS OF GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONISTS AND EVALUATION OF THEIR MOLECULAR MODELING

  2011cites this paper
• The Prevention of Atherothrombotic Events in Adults with Acute Coronary Syndromes

  2011cites this paper
• [Patient after acute coronary syndrome on antiplatelet therapy. Inhibition of coagulation processes may decrease the occurence of major cardiovascular events].

  2010cites this paper
• Coronary Heart Disease Two-Year Follow-Up of Tirofiban-Based Management of Non-ST-Elevation Acute Coronary Syndrome A Single Center Study

  2010cites this paper
• G‐protein β3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes–thrombolysis in myocardial infarction 16 trial

  2010cites this paper
• Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

  2010cites this paper
• Anticoagulants: newer ones, mechanisms, and perioperative updates.

  2010cites this paper
• GUIDELINES FOR PRE-OPERATIVE CARDIAC RISK ASSESSMENT AND PERIOPERATIVE CARDIAC MANAGEMENT IN NON-CARDIAC SURGERY

  2010cites this paper
• Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease

  2010cites this paper
• Estratificación del riesgo en el infarto agudo de miocardio según el índice leucoglucémico. ¿El "Killip-Kimball" de laboratorio?

  2010cites this paper
• Two-Year Follow-Up of Tirofiban-Based Management of Non-ST-Elevation Acute Coronary Syndrome-A Single Center Study

  2010cites this paper
• Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.

  2010cites this paper
• Prior aspirin use and outcomes in acute coronary syndromes.

  2010cites this paper
• Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions

  2010cites this paper
• CHAPTER 14 – Medical Management of Unstable Angina and Non–ST Segment Elevation Myocardial Infarction

  2010cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the Europe

  2010cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery

  2009cites this paper
• Validation of an Automated Safety Surveillance System with Prospective, Randomized Trial Data

  2009cites this paper
• Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs

  2009cites this paper
• Kalp dişi cerrahide preoperatif kardiyak riskin değerlendirilmesi ve perioperatif kardiyak tedaviye ilişkin kilavuzlar Avrupa Kardiyoloji Derneği (ESC) tarafindan hazirlanan ve Avrupa Anesteziyoloji Derneği (ESA) tarafindan onaylanan Kalp Dişi Cerrahide Preoperatif Kardiyak Riskin Değerlendirilmesi

  2009cites this paper
• Changes in plasma brain natriuretic peptide in conventional or direct stenting

  2009cites this paper
• Antithrombotic therapy after acute myocardial infarction

  2009cites this paper
• Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca

  2009cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European of Cardiology the of Anaesthesiology

  2009cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European of Cardiology the of Anaesthesiology

  2009cites this paper
• Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery.

  2009cites this paper
• [TIMI group study of thrombolysis in myocardial infarction].

  2009cites this paper
• Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.

  2009cites this paper
• Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).

  2009cites this paper
• Perioperative Cardiac Care: from Guidelines to Clinical Practice

  2008cites this paper
• The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.

  2008cites this paper
• Recent developments in acute coronary syndromes.

  2008cites this paper
• Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials

  2008cites this paper
• Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16

  2008cites this paper
• Bleeding Risks with Prasugrel in the TRITON Trial: Good News ... Bad News

  2008cites this paper
• [Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].

  2008cites this paper
• Pharmacogenomics in acute coronary syndrome

  2008cites this paper
• Prasugrel development – Claims and achievements

  2008cites this paper
• Regulation of Tissue Factor and Coagulation Activity : Translation Studies with Focus on Platelet-Monocyte Aggregates and Patients with Acute Coronary Syndrome

  2008cites this paper
• Use of antiplatelet agents for prevention of ischemic stroke.

  2008cites this paper
• The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

  2008cites this paper
• Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.

  2008cites this paper
• Bleeding risks of combination vs. single antiplatelet therapy: a meta‐analysis of 18 randomized trials comprising 129 314 patients

  2008cites this paper
• Chapter 5 – Pharmacologic Options for Treatment of Ischemic Disease

  2007cites this paper
• Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.

  2007cites this paper
• ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie

  2007cites this paper
• Perceived Disability and Lifestyle Modification Following Hospitalization for Non-ST Elevation Versus ST Elevation Acute Coronary Syndromes: The Patients' Point of View

  2007cites this paper
• Diabetes and mortality following acute coronary syndromes.

  2007cites this paper
• ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY

  2007cites this paper